Silphium Asset Management’s Standard BioTools LAB Stock Holding History

Silphium Asset Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-28,813	Closed	-$216K	–	74
2018 Q3	$216K	Buy	+28,813	New	+$205K	0.06%	109
2018 Q2	–	Sell	-15,848	Closed	-$92.6K	–	129
2018 Q1	$92.6K	Buy	+15,848	New	+$104K	0.05%	74

Other funds holding LAB

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Silphium Asset Management's LAB Position: Q4 2018 in Review

Silphium Asset Management sold out of Standard BioTools (LAB) in Q4 2018, closing a stake of 28,813 shares — an estimated $216K sold.

Silphium Asset Management first reported a position in LAB in Q1 2018 and held it in 2 quarters. The position peaked at $216K in Q3 2018. 99 funds tracked by Wall St. Rank hold LAB as of Q4 2018.

Silphium Asset Management reported no remaining Standard BioTools position as of Q4 2018 after selling out during the quarter.
Silphium Asset Management sold 28,813 Standard BioTools shares in Q4 2018, an estimated $216K.
Silphium Asset Management first reported a position in Standard BioTools in Q1 2018 and held it in 2 quarters.
Silphium Asset Management's Standard BioTools position peaked at $216K in Q3 2018.
99 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2018.

Based on Silphium Asset Management's 13F filing for Q4 2018, filed 30 Jan 2025.